stoxline Quote Chart Rank Option Currency Glossary
Qualigen Therapeutics, Inc. (QLGN)
0.73  0.02 (2.8%)    12-01 15:41
Open: 0.7101
High: 0.7375
Volume: 5,587
Pre. Close: 0.7101
Low: 0.7008
Market Cap: 4(M)
Technical analysis
2023-12-01 4:22:14 PM
Short term     
Mid term     
Targets 6-month :  0.91 1-year :  1.01
Resists First :  0.78 Second :  0.87
Pivot price 0.71
Supports First :  0.64 Second :  0.54
MAs MA(5) :  0.7 MA(20) :  0.7
MA(100) :  0.93 MA(250) :  1.04
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  50.5 D(3) :  45.6
RSI RSI(14): 47.2
52-week High :  1.92 Low :  0.64
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ QLGN ] has closed below upper band by 22.3%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.74 - 0.74 0.74 - 0.74
Low: 0.69 - 0.7 0.7 - 0.7
Close: 0.72 - 0.73 0.73 - 0.74
Company Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Headline News

Mon, 27 Nov 2023
QLGN: Dosing Begins in Phase 1 Trial of QN-302… - Yahoo Finance

Tue, 14 Nov 2023
Qualigen Therapeutics Provides Corporate Update for Third Quarter ... - GlobeNewswire

Tue, 07 Nov 2023
Qualigen Therapeutics Announces First Patient Dosed in the Phase ... - BioSpace

Wed, 27 Sep 2023
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR ... - Yahoo Finance

Tue, 15 Aug 2023
Qualigen Therapeutics, Inc. Reports Financial Results and ... - BioSpace

Tue, 01 Aug 2023
Qualigen Therapeutics Announces US FDA IND Clearance to ... - BioSpace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 5 (M)
Shares Float 5 (M)
Held by Insiders 11.5 (%)
Held by Institutions 2.1 (%)
Shares Short 40 (K)
Shares Short P.Month 44 (K)
Stock Financials
EPS -4.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.32
Profit Margin 0 %
Operating Margin -314.1 %
Return on Assets (ttm) -71.8 %
Return on Equity (ttm) -290.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0.13
Sales Per Share 0.96
EBITDA (p.s.) -2.96
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.18
PEG Ratio 0
Price to Book value -2.29
Price to Sales 0.75
Price to Cash Flow -0.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android